Shares of e-therapeutics plc (LON:ETX – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 10.74 ($0.14) and traded as low as GBX 9 ($0.12). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares trading hands.
e-therapeutics Stock Down 6.7 %
The company has a debt-to-equity ratio of 0.33, a current ratio of 22.20 and a quick ratio of 20.13. The company’s 50-day simple moving average is GBX 9 and its 200 day simple moving average is GBX 10.68. The firm has a market cap of £52.59 million, a P/E ratio of -450.00 and a beta of 0.46.
e-therapeutics Company Profile
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Recommended Stories
- Five stocks we like better than e-therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Investing in Travel Stocks Benefits
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.